|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
1994-6-30
|
|
pubmed:abstractText |
The prevailing view is that supraspinal mu opioid-mediated antinociception in mice is mediated via the mu 1 subtype. The purpose of the present study was to determine if the highly mu-selective compound etonitazene could produce supraspinal (intracerebroventricular; i.c.v.) antinociception in CXBK mice, which are deficient in brain mu1, but not mu2, opioid receptors. CXBK or normal Crl:CD-1 (ICR)BR mice were administered graded doses of etonitazene i.c.v. and 15 min later antinociception was assessed by a standard radiant-heat or 55 degrees C water tail-flick test. Etonitazene produced dose-related antinociception that was blocked by naloxone and by beta-FNA (demonstrating a mu opioid mechanism), but not by either ICI-174,864 or naltrindole (demonstrating the lack of involvement of delta opioid receptors). These findings suggest that mu2 opioid receptors are important contributors to opioid-induced supraspinal antinociception in mice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Enkephalin, Leucine,
http://linkedlifedata.com/resource/pubmed/chemical/N,N-diallyl-tyrosyl-alpha-aminoisobu...,
http://linkedlifedata.com/resource/pubmed/chemical/Naloxone,
http://linkedlifedata.com/resource/pubmed/chemical/Naltrexone,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotic Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, mu,
http://linkedlifedata.com/resource/pubmed/chemical/beta-funaltrexamine,
http://linkedlifedata.com/resource/pubmed/chemical/naltrindole
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0024-3205
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
PL369-74
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:7910928-Animals,
pubmed-meshheading:7910928-Benzimidazoles,
pubmed-meshheading:7910928-Cerebral Ventricles,
pubmed-meshheading:7910928-Dose-Response Relationship, Drug,
pubmed-meshheading:7910928-Enkephalin, Leucine,
pubmed-meshheading:7910928-Hot Temperature,
pubmed-meshheading:7910928-Injections, Intraventricular,
pubmed-meshheading:7910928-Injections, Subcutaneous,
pubmed-meshheading:7910928-Male,
pubmed-meshheading:7910928-Mice,
pubmed-meshheading:7910928-Mice, Inbred ICR,
pubmed-meshheading:7910928-Mice, Mutant Strains,
pubmed-meshheading:7910928-Naloxone,
pubmed-meshheading:7910928-Naltrexone,
pubmed-meshheading:7910928-Narcotic Antagonists,
pubmed-meshheading:7910928-Pain,
pubmed-meshheading:7910928-Receptors, Opioid, mu,
pubmed-meshheading:7910928-Spinal Cord
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Etonitazene-induced antinociception in mu1 opioid receptor deficient CXBK mice: evidence for a role for mu2 receptors in supraspinal antinociception.
|
|
pubmed:affiliation |
R.W. Johnson Pharmaceutical Research Institute, Spring House, PA 19477.
|
|
pubmed:publicationType |
Journal Article
|
